Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.
作者信息
Steinebrunner Niels, Stremmel Wolfgang, Weiss Karl H
机构信息
Department of Gastroenterology and Hepatology, University Hospital Heidelberg, Heidelberg, Germany.
出版信息
J Thorac Dis. 2018 Jan;10(1):118-120. doi: 10.21037/jtd.2017.12.117.
Abstract
摘要
相似文献
1
Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.利迪尼唑——一种用于治疗艰难梭菌感染的新型抗生素。
J Thorac Dis. 2018 Jan;10(1):118-120. doi: 10.21037/jtd.2017.12.117.
2
Ridinilazole: a novel antimicrobial for infection.利迪尼唑：一种用于感染的新型抗菌药物。
Ann Gastroenterol. 2019 Mar-Apr;32(2):134-140. doi: 10.20524/aog.2018.0336. Epub 2018 Dec 13.
3
Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection.新型艰难梭菌感染治疗药物瑞地那唑（SMT19969）对艰难梭菌毒素产生及细胞形态的影响
J Antimicrob Chemother. 2016 May;71(5):1245-51. doi: 10.1093/jac/dkv498. Epub 2016 Feb 18.
4
Ridinilazole for the treatment of Clostridioides difficile infection.利福昔明治疗艰难梭菌感染。
Expert Opin Investig Drugs. 2019 Apr;28(4):303-310. doi: 10.1080/13543784.2019.1582640. Epub 2019 Feb 26.
5
A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile.一种用于成像抗生素治疗艰难梭菌药理作用的新方法。
Anaerobe. 2016 Aug;40:10-4. doi: 10.1016/j.anaerobe.2016.04.013. Epub 2016 Apr 21.
6
Update of treatment algorithms for Clostridium difficile infection.艰难梭菌感染治疗方案的更新。
Clin Microbiol Infect. 2018 May;24(5):452-462. doi: 10.1016/j.cmi.2017.12.022. Epub 2018 Jan 6.
7
Novel Antimicrobials for the Treatment of Infection.用于治疗感染的新型抗菌药物。
Front Med (Lausanne). 2018 Apr 16;5:96. doi: 10.3389/fmed.2018.00096. eCollection 2018.
8
Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?艰难梭菌感染的治疗——除了甲硝唑和万古霉素之外还有什么新进展吗？
Expert Rev Clin Pharmacol. 2017 Nov;10(11):1239-1250. doi: 10.1080/17512433.2017.1362978. Epub 2017 Aug 11.
9
New antibiotics in clinical trials for Clostridium difficile.用于艰难梭菌临床试验的新型抗生素。
Expert Rev Anti Infect Ther. 2016;14(9):789-800. doi: 10.1080/14787210.2016.1211931. Epub 2016 Jul 25.
10
Microbiologic factors affecting Clostridium difficile recurrence.影响艰难梭菌复发的微生物因素。
Clin Microbiol Infect. 2018 May;24(5):476-482. doi: 10.1016/j.cmi.2017.11.017. Epub 2017 Dec 5.
引用本文的文献
1
Antibiotics in the pipeline: a literature review (2017-2020).正在研发中的抗生素：文献综述（2017-2020 年）。
Infection. 2022 Jun;50(3):553-564. doi: 10.1007/s15010-021-01709-3. Epub 2021 Oct 4.
2
A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against .一种用于评估2-氨基咪唑分子治疗潜力的小分子筛选流程 针对……
Front Microbiol. 2018 Jun 6;9:1206. doi: 10.3389/fmicb.2018.01206. eCollection 2018.
本文引用的文献
1
Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.利地硝唑与万古霉素治疗艰难梭菌感染的疗效和安全性比较：一项2期随机双盲活性对照非劣效性研究。
Lancet Infect Dis. 2017 Jul;17(7):735-744. doi: 10.1016/S1473-3099(17)30235-9. Epub 2017 Apr 28.
2
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.贝洛妥珠单抗预防复发性艰难梭菌感染。
N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615.
3
New and emerging therapies for Clostridium difficile infection.艰难梭菌感染的新型及新兴疗法
Curr Opin Infect Dis. 2016 Dec;29(6):546-554. doi: 10.1097/QCO.0000000000000320.
4
Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection.新型艰难梭菌感染治疗药物瑞地那唑（SMT19969）对艰难梭菌毒素产生及细胞形态的影响
J Antimicrob Chemother. 2016 May;71(5):1245-51. doi: 10.1093/jac/dkv498. Epub 2016 Feb 18.
5
Breakthroughs in the treatment and prevention of Clostridium difficile infection.艰难梭菌感染治疗和预防的突破。
Nat Rev Gastroenterol Hepatol. 2016 Mar;13(3):150-60. doi: 10.1038/nrgastro.2015.220. Epub 2016 Feb 10.
6
A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.一项随机1期研究，旨在调查新型艰难梭菌感染治疗药物SMT19969在健康男性受试者中单次及多次口服给药后的安全性、药代动力学以及对肠道微生物群的影响。
BMC Infect Dis. 2015 Feb 25;15:91. doi: 10.1186/s12879-015-0759-5.
7
Burden of Clostridium difficile infection in the United States.美国艰难梭菌感染的负担
N Engl J Med. 2015 Feb 26;372(9):825-34. doi: 10.1056/NEJMoa1408913.
8
Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection.口服、胶囊化、冷冻粪菌移植治疗复发性艰难梭菌感染。
JAMA. 2014 Nov 5;312(17):1772-8. doi: 10.1001/jama.2014.13875.
9
Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review.艰难梭菌感染复发、并发症及死亡率的危险因素：一项系统评价
PLoS One. 2014 Jun 4;9(6):e98400. doi: 10.1371/journal.pone.0098400. eCollection 2014.
10
Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation.活化T细胞核因子调控基因的残余基因表达降低与肝移植后巨细胞病毒感染风险相关。
Transpl Infect Dis. 2014 Jun;16(3):379-86. doi: 10.1111/tid.12206. Epub 2014 Mar 26.
Zotero 插件